Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
TRABID CRISPR Activation Plasmid (h): sc-402852-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- TRABID CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- TRABID CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by TRABID CRISPR Activation Plasmid (h) and TRABID CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the ZRANB1 transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: TRABID Antibody (F-1): sc-374377
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TRABID CRISPR Activation Plasmid (h) | sc-402852-ACT | 20 µg | $397.00 |
Human ZRANB1 encodes TRABID, an OTU family deubiquitinase that preferentially cleaves K29- and K33-linked polyubiquitin chains to remodel ubiquitin-dependent signaling. TRABID has been implicated in regulating Wnt/β-catenin transcriptional programs and NF-κB-associated inflammatory signaling through modulation of ubiquitinated pathway components, influencing gene expression and cellular homeostasis. By editing ubiquitin chain topology, TRABID contributes to control of protein stability and signal propagation in contexts such as proliferation, differentiation, and stress responses. Dysregulation of these pathways links TRABID-related mechanisms to cancer biology, immune signaling perturbations, and other disease-relevant cellular phenotypes that can be interrogated in model systems.
TRABID CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous ZRANB1 expression without altering the underlying DNA sequence.
TRABID CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the ZRANB1 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the ZRANB1 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous TRABID expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native ZRANB1 locus and enabling the study of TRABID-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of TRABID pathway restoration in tumor cells with silenced or reduced ZRANB1 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.